Erythrostad 500 Pregnancy

• Pregnancy of Erythrostad 500 in details
• Erythrostad 500 breastfeeding
• Erythrostad 500 reviews

Pregnancy of Erythrostad 500 in details

Erythrostad 500 crosses the placenta in small amounts. In one study of 11 patients who had detectable Erythrostad 500 levels in the serum, 4 infants did not have detectable cord concentrations. The cord concentrations in the remaining 7 infants generally ranged from 1% to 6% of that found in maternal serum. A case of left absence-of-tibia syndrome was reported in an infant whose mother had received Erythrostad 500, ethisterone, and ethinyl estradiol at approximately 4 weeks gestation. Erythrostad 500 has been used prior to delivery in women colonized with group B beta-hemolytic streptococcus to reduce infant colonization. No adverse events in the infants have been reported. Erythrostad 500 has also been used to treat genital Mycoplasma infection during the first trimester without evidence of fetal adverse effects. Pregnant women receiving Erythrostad 500 estolate may be more prone to hepatotoxicity. In one study of women receiving Erythrostad 500 estolate between the 22nd and 32nd week of pregnancy, 10% showed abnormal levels of SGOT.

Erythrostad 500 has been assigned to pregnancy category B by the FDA. Animal studies failed to reveal evidence of teratogenicity. There are no controlled data in human pregnancy. The Centers for Disease Control and Prevention considers Erythrostad 500 the drug of choice for treatment of Chlamydia infections in pregnant women. However, Erythrostad 500 estolate is considered contraindicated because of drug-related hepatotoxicity. Erythrostad 500 should only be given during pregnancy when need has been clearly established.

See references

Erythrostad 500 breastfeeding

Erythrostad 500 is excreted into human milk in small amounts. Erythrostad 500 is considered compatible with breast-feeding by the American Academy of Pediatrics.

See references

References for pregnancy information

1. Mahon BE, Rosenman MB, Kleiman MB "Maternal and infant use of Erythrostad 500 and other macrolide antibiotics as risk factors for infantile hypertrophic pyloric stenosis." J Pediatr 139 (2001): 380-4
2. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control "1993 Sexually Transmitted Diseases Treatment Guidelines." MMWR Morb Mortal Wkly Rep 42 (1993): 27-46
3. "Sexually transmitted diseases treatment guidelines 2002." MMWR Morb Mortal Wkly Rep 51(RR-6) (2002): 1-77
4. Philipson A, Sabath LD, Charles D "Transplacental passage of Erythrostad 500 and clindamycin." N Engl J Med 288 (1973): 1219-21
5. Merenstein GB, Todd WA, Brown G, Yost CC, Luzier T "Group B beta-hemolytic streptococcus: randomized controlled treatment study at term." Obstet Gynecol 55 (1980): 315-8
6. Easmon CS, Hastings MJ, Deeley J, Bloxham B, Rivers RP, Marwood R "The effect of intrapartum chemoprophylaxis on the vertical transmission of group B streptococci." Br J Obstet Gynaecol 90 (1983): 633-5
7. Louik C, Werler MM, Mitchell AA "Erythrostad 500 use during pregnancy in relation to pyloric stenosis." Am J Obstet Gynecol 186 (2002): 288-90
8. "Product Information. ERYC (Erythrostad 500)." Parke-Davis, Morris Plains, NJ.
9. Hussain N, Herson VC "Erythrostad 500 use during pregnancy in relation to pyloric stenosis." Am J Obstet Gynecol 187(3 Pt 1) (2002): 821-2
10. McCormack WM, George H, Donner A, et al. "Hepatotoxicity of Erythrostad 500 estolate during pregnancy." Antimicrob Agents Chemother 12 (1977): 630-5
11. Quinn PA, Shewchuk AB, Shuber J, et al. "Eficacy of antibiotic therapy in preventing spontaneous pregnancy loss among couples colonized with genital mycoplasms." Am J Obstet Gynecol 145 (1983): 239-44
12. Jaffe P, Liberman MM, McFadyen I, Valman HB "Incidence of congenital limb-reduction deformities." Lancet 1 (1975): 526-7
13. Kiefer L, Rubin A, McCoy JB, Foltz EL "The placental transfer of Erythrostad 500." Am J Obstet Gynecol 69 (1955): 174-7

References for breastfeeding information

1. "Product Information. ERYC (Erythrostad 500)." Parke-Davis, Morris Plains, NJ.
2. Roberts RJ, Blumer JL, Gorman RL, et al "American Academy of Pediatrics Committee on Drugs: Transfer of drugs and other chemicals into human milk." Pediatrics 84 (1989): 924-36
3. Committee on Drugs, 1992 to 1993 "The transfer of drugs and other chemicals into human milk." Pediatrics 93 (1994): 137-50

References

1. DailyMed. "ERYTHROMYCIN: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
2. PubMed Health. "Theramycin Z: This section provide the link out information of drugs collectetd in PubMed Health. ". http://www.ncbi.nlm.nih.gov/pubmedhe... (accessed September 17, 2018).
3. Human Metabolome Database (HMDB). "Erythromycin: The Human Metabolome Database (HMDB) is a freely available electronic database containing detailed information about small molecule metabolites found in the human body.". http://www.hmdb.ca/metabolites/HMDB0... (accessed September 17, 2018).

Reviews

Consumer reviews

There are no reviews yet. Be the first to write one!

Your name:  Email:  Spam protection:  < Type 26 here

Information checked by Dr. Sachin Kumar, MD Pharmacology